
Opinion|Videos|December 7, 2023
Choosing Between Available Combination BRAF/MEK Inhibitor Options for Patients With BRAF-Mutated Metastatic Melanoma
The panel explains which BRAF/MEK inhibitor combination therapy they each tend to turn to when treating a patient with BRAF-mutated metastatic melanoma.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on OncLive
1
Daraxonrasib Plus Gemcitabine/Nab-Paclitaxel Generates Durable Responses in First-Line Metastatic PDAC
2
Dr Iyengar on Oral SERD Implementation in Early-Stage HR+ Breast Cancer
3
TroFuse-015 Meets Primary OS End Point With Sac-TMT in Third-Line or Later Gastroesophageal Adenocarcinoma
4
Dr Leighl on HARMONi Survival Data and the FDA's Decision on Ivonescimab in Previously Treated EGFR-Mutated NSCLC
5


